The U.S. Food and Drug Administration has approved roflumilast, an oral drug that reduces exacerbations from severe chronic obstructive pulmonary disease (COPD). Read more at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm244989.htm
The U.S. Food and Drug Administration has approved roflumilast, an oral drug that reduces exacerbations from severe chronic obstructive pulmonary disease (COPD). Read more…
Reader Survey
Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.